Primary Sclerosing Cholangitis

Seminars in Gastrointestinal Disease

Volumn 14, Issue 4, 2003, Pages 189-198

  Rodriguez, Harry J ^a   Bass, Nathan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIARY CIRRHOSIS; BILIARY TRACT FIBROSIS; CASE REPORT; CHOLESTASIS; COLON CARCINOMA; COMMON BILE DUCT STONE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPY; ENTERITIS; FEMALE; GENETIC PREDISPOSITION; HUMAN; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; OSTEOPOROSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; VITAMIN DEFICIENCY;

EID: 0348223703     PISSN: 10495118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Boberg KM, Aadland E, Jahnsen J, et al: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33:99-103, 1998
2. Olsson R, Jarnerot G: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100:1319-1323, 1991
3. Wiesner RH, Grambsch PM, Dickson ER, et al: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 10:430-436, 1989
4. Mahadevan U, Bass NM: Sclerosing cholangitis and recurrent pyogenic cholangitis, in Feldman M, Friedman LS, Sleisinger MH (eds): Gastrointestinal Disease. ed 7. Philadelphia, PA, Saunders, 2002, pp 1131-1152
5. Okada H, Mizuno M, Yamamoto K, et al. Primary sclerosing cholangitis in Japanese patients: Association with inflammatory bowel disease. Acta Med Okayama 50:227-235, 1996
6. Feldstein AE, Perrault J, El-Youssif M, et al: Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 38:210-217, 2003
7. Mitchell SA, Thyssen M, Orchard TR, et al: Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: A case control study. Gut 51:567-573, 2002
8. Chalasani N, Baluyut A, Ismail A, et al: Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31:7-11, 2000
9. Quigley EM, LaRusso NF, Ludwig J, et al: Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 85:1160-1165, 1983
10. Habior A, Rawa T, Orlowska J, et al: Association of primary sclerosing cholangitis, ulcerative colitis and coeliac disease in female siblings. Eur J Gastroenterol Hepatol 14:787-791, 2002
11. Moloney MM, Thomson LJ, Strettell MJ, et al: Human leukocyte antigen-C genes and susceptibility to primary sclerosing cholangitis. Hepatology 28:660-662, 1998
12. Prochazka EJ, Terasaki PI, Park MS, et al: Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 322:1842-1844, 1990
13. Saarinen S, Olerup O, Broome U: Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 95:3195-3199, 2000
14. Olerup O, Olsson R, Hultcrantz R, et al: HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 108:870-878, 1995
15. Mitchell SA, Grove J, Spurkland A, et al: Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 49:288-294, 2001
16. Angulo P, Peter JB, Gershwin ME, et al: Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 32:182-187, 2000
17. Xu B, Broome U, Ericzon BG, et al: High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51:120-127, 2002
18. Targan SR, Lander C, Vidrich A, et al: High-titer antineutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Gastroenterology 108:1159-1166, 1995
19. Schwarze C, Terjung B, Lilienweiss P, et al: IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol 133:283-289, 2003
20. Orth T, Gerken G, Kellner R, et al: Actin is a target of antineutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. J Hepatology 26:37-47, 1997
21. Gregorio GV, Portmann B, Karani J, et al: Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 33:544-553, 2001
22. Van Buuren HR, van Hoogstraten HJE, Terkivatan T, et al: High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 33:543-548, 2000
23. Siegel JH, Barnes S, Morris JS: Bile acids in liver disease associated with inflammatory bowel disease. Digestion 15:469-481, 1977
24. Wilcox CM, Monkemuller KE: Hepatobiliary diseases in patients with AIDS: Focus on AIDS cholangiopathy and gallbladder disease. Dig Dis 16:205-213, 1998
25. Mehal WZ, Hattersley AT, Chapman RW, et al: A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J Hepatol 15:396-399, 1992
26. Minuk GY, Rascanin N, Paul RW, et al: Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 5:8-13, 1987
27. Farkkila M, Karkkainen P, Karvonen AL, et al: Combination of UDCA and metronidazole in PSC: Reduction of inflammation in liver correlates with the decrease of the new Mayo risk score. Gastroenterology 124:A-707, 2003 (abstr)
28. Baluyut AR, Sherman S, Lehman GA, et al: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53:308-312, 2001
29. Ludwig J, LaRusso NF, Wiesner RH, et al: The syndrome of primary sclerosing cholangitis. Prog Liver Dis 9:556-566, 1990
30. Lee YM, Kaplan MM: Practice guideline committee of the ACG. American College of Gastroenterology. Management of primary sclerosing cholangitis. Am J Gastroenterol 97:528-534, 2002
31. Ludwig J, Barham SS, LaRusso NF, et al: Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1:632-640, 1981
32. Ludwig J, Czaja AJ, Dickson ER, et al: Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: Morphologic spectrum, clinical correlations and terminology. Liver 4:105-116, 1984
33. Angulo P, Maor-Kendler Y, Lindor KD: Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology 35:1494-1500, 2002
34. Dienes HP, Erberich H, Dries V, et al: Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 6:349-362, 2002
35. Abdo AA, Bain VG, Kichian K, et al: Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 36:1393-1399, 2002
36. Muratori L, Cassani F, Pappas G, et al: The hepatitic/ cholestatic "overlap" syndrome: An Italian experience. Autoimmunity 35:565-568, 2002
37. Stiehl A, Benz C, Sauer P: Primary sclerosing cholangitis. Can J Gastroenterol 14:311-315, 2000
38. Levy C, Lindor KD: Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Treat Options Gastroenterol 6:93-103, 2003
39. Mitchell SA, Bansi DS, Hunt N, et al: A preliminary trial of high dose ursodeoxycholic acid in PSC. Gastroenterology 121:900-907, 2001
40. Pardi DS, Loftus EV Jr, Kremers WK, et al: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889-893, 2003
41. Broome U, Lofberg R, Veress B, et al: Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 22:1404-1408, 1995
42. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al: Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51:562-566, 2002
43. Farrant J, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100:1710-1717, 1991
44. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 69:1633-1637, 2000
45. Gores GJ: Cholangiocarcinoma: Current concepts and insights. Hepatology 37:961-999, 2003
46. Isaia G, Di Stefano M, Roggia C, et al: Bone disorders in cholestatic liver diseases. Forum (Genova) 8:28-38, 1998
47. Guichelaar MM, Malinchoc M, Sibonga J, et al: Bone metabolism in advanced cholestatic liver disease: Analysis by bone histomorphometry. Hepatology 36:895-903, 2002
48. Graziadei IW, Wiesner RH, Marotta PJ, et al: Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30:1121-1127, 1999
49. Wiesner RH: Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 15:667-680, 2001
50. Gow PJ, Chapman RW: Liver transplantation for primary sclerosing cholangitis. Liver 20:97-103, 2000
51. Graziadei IW: Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transplant 8:575-581, 2002
52. Kugelmas M, Spiegelman P, Osgood MJ, et al: Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transplant 9:727-732, 2003
53. Kim WR, Therneau TM, Wiesner RH, et al: A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75:688-694, 2000
54. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al: Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 51:562-566, 2002